Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Completed · Phase 2 · Has a placebo group
Conditions studied: Type 2 Diabetes Mellitus With Diabetic Nephropathy
In brief
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor. The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone system.
Key facts
- Study ID
- NCT02010242
- Run by
- Calliditas Therapeutics AB
- People needed
- 136
- Starts
- 2013-10-01
- Expected to finish
- 2015-03-01
- Last updated by the study team
- 2025-02-28
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Advanced Arizona Clinical Research — Tucson, Arizona, United States
- The Endocrine Medical Group, Inc — Orange, California, United States
- Clinical Research of South Florida — Coral Gables, Florida, United States
- The Center for Diabetes and Endocrine Care — Hollywood, Florida, United States
- Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
- Genoma Research Group, Inc. — Miami, Florida, United States
- Coral Research Clinic — Miami, Florida, United States
- Pines Clinical Research Inc. — Pembroke Pines, Florida, United States
- Volunteer Medical Research — Port Charlotte, Florida, United States
- John H. Stroger Jr. Hospital of Cook County — Chicago, Illinois, United States
- Community Medical Research Partners — Indianapolis, Indiana, United States
- Kansas City VA Medical Center — Kansas City, Missouri, United States
- Creighton Diabetes Center — Omaha, Nebraska, United States
- LLC DBA AccessMD Clinical Research — Dayton, Ohio, United States
- Southeast Renal Research Institute — Chattanooga, Tennessee, United States
- The University of Texas Southwestern Medical Center — Dallas, Texas, United States
- 17070 Red Oak dr Ste 103 — Houston, Texas, United States
- Dialysis West University Health System — San Antonio, Texas, United States
- McGuire VA Medical Center — Richmond, Virginia, United States
- Zablocki VAMC — Milwaukee, Wisconsin, United States
- Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
- Deakin University school of medicine — Geelong, Victoria, Australia
- Austin Health — Heidelberg, Victoria, Australia
- Baker Institute — Melbourne, Victoria, Australia
- Maroondah ECRU — Ringwood East, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.